Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE studyDarryl C. De Vivo, Wildon Farwell, Enrico Bertini et al.|Neuromuscular Disorders|2019Cited by 636
Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of the<scp>NURTURE</scp>studyThomas O. Crawford, Kathryn J. Swoboda, Darryl C. De Vivo et al.|Muscle & Nerve|2023Cited by 117
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trialThomas O. Crawford, Barbara Steinborn, Guolin Zhao et al.|The Lancet Neurology|2025Cited by 22
Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History ComparisonsCraig M. McDonald, Michela Guglieri, Dragana Vučinić et al.|Annals of Clinical and Translational Neurology|2025Cited by 12
Pamrevlumab did not meet its primary endpoint for ambulatory patients with Duchenne Muscular Dystrophy: the LELANTOS-2 trialBrenda Wong, H. Phan, Yann Péréon et al.|medRxiv|2025Cited by 2